VEGFA and colorectal carcinoma: As demonstrated in Figures 3B and D, VEGF-A treatment of HT29 and KM12L4 human CRC cells resulted in a five- and three-fold increases in cellular migration, respectively, over nontreated control cells (P<0.001).